AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18507579 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support during labor and delivery
Number of subjects: 420
Study 18507579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no doula support)
Number of subjects: 420
Study 18507579 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support during induced labor
Number of subjects: 420
Study 18507579 — intervention group
Group type: COMPARATOR
Intervention: Control group during induced labor
Number of subjects: 420
Study 18507579 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support overall experience
Number of subjects: 420
Study 17040520 — intervention group
Group type: EXPERIMENTAL
Intervention: New facility policy on restraints (bedrails not to be used except under specified conditions)
Number of subjects: 0
Study 17040520 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine use of bedrails according to the old policy)
Number of subjects: 0
Study 12940872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine, 10 mg once daily
Number of subjects: 40
Study 12940872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11885173 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in the study
Number of subjects: 0
Study 11885173 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified analysis of data up to 72 months after implant uncovering
Number of subjects: 0
Study 8833025 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically based, structured experimental treatment program
Number of subjects: 32
Study 8833025 — intervention group
Group type: COMPARATOR
Intervention: Relatively unstructured comparison intervention
Number of subjects: 32
Study 1467099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil loading dose of 85 micrograms kg‐1 and infusion of 65 micrograms kg‐1 h‐1
Number of subjects: 59
Study 1467099 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil loading dose of 65 micrograms kg‐1 and infusion of 50 micrograms kg‐1 h‐1
Number of subjects: 59
Study 6205337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-dichlorodiammineplatinum(II) (cis-DDP) 33 mg/kg i.v. day 1 and Bleomycin (BLM) 15 mg/m2 i.v. continuously day 2-6 (arm A)
Number of subjects: 79
Study 6205337 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) 30 mg/m2 i.v. day 1 + 6 and Vindesine (VDS) 3 mg/m2 day 2 + 7 (arm B)
Number of subjects: 79
Study 6205337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (both arms combined)
Number of subjects: 79
Study 6205337 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery +/− radiotherapy (in not pretreated patients)
Number of subjects: 79
Study 31400105 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based parenting education including unintentional injury prevention
Number of subjects: 1980
Study 31400105 — intervention group
Group type: COMPARATOR
Intervention: App-based parenting education excluding unintentional injury prevention
Number of subjects: 1980
Study 29659797 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg b.i.d., reduced to 2.5 mg b.i.d. if applicable)
Number of subjects: 1500
Study 29659797 — intervention group
Group type: COMPARATOR
Intervention: Heparin/Vitamin K Antagonist (VKA)
Number of subjects: 1500
Study 29659797 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1500
Study 27282597 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4046
Study 27282597 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 4046
Study 23336612 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical training and written guidance
Number of subjects: 62
Study 23336612 — intervention group
Group type: EXPERIMENTAL
Intervention: Training, written guidance, and TIM tubes
Number of subjects: 62
Study 23336612 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical training and TIM tubes
Number of subjects: 62
Study 23336612 — intervention group
Group type: COMPARATOR
Intervention: Written guidance only
Number of subjects: 62
Study 21908169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system for total knee arthroplasty (Visionaire; Smith & Nephew, Inc, Memphis, Tenn) (VIS)
Number of subjects: 29
Study 21908169 — intervention group
Group type: COMPARATOR
Intervention: Standard TKA surgical instrumentation (STD)
Number of subjects: 29
Study 21908169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-matched instrument system for total knee arthroplasty (VIS)
Number of subjects: 29
Study 20106358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (n = 198)
Number of subjects: 719
Study 20106358 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery (n = 196)
Number of subjects: 719
Study 20106358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial artery (n = 113)
Number of subjects: 719
Study 20106358 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein (n = 112)
Number of subjects: 719
Study 17286868 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 70/30)
Number of subjects: 233
Study 17286868 — intervention group
Group type: COMPARATOR
Intervention: Glargine (Glar)
Number of subjects: 233
Study 15643230 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg Serenoa repens (SR) orally twice daily for 3 months
Number of subjects: 29
Study 15643230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 3 weeks before surgery)
Number of subjects: 29
Study 12217676 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 0
Study 12217676 — intervention group
Group type: COMPARATOR
Intervention: Conventional discectomy
Number of subjects: 0
Study 12217676 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous discectomy
Number of subjects: 0
Study 10972952 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Hz magnetic fields at a resultant flux density of 28.3 microT
Number of subjects: 24
Study 10972952 — intervention group
Group type: COMPARATOR
Intervention: Previous studies with intermittent exposure to 60 Hz magnetic fields
Number of subjects: 24
Study 8997576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution (0.3%)
Number of subjects: 39
Study 8997576 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid gel (1%)
Number of subjects: 39
Study 1360665 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant gp160 vaccine
Number of subjects: 26
Study 1360665 — intervention group
Group type: COMPARATOR
Intervention: recombinant hepatitis B vaccine (control)
Number of subjects: 26
Study 6142907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2 to 6 mg/day)
Number of subjects: 32
Study 6142907 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (0.8 to 2.4 g/day)
Number of subjects: 32
Study 6142907 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (6.3 mg/day after crossover)
Number of subjects: 32
Study 6142907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 32
Study 29480087 — intervention group
Group type: EXPERIMENTAL
Intervention: Running and brisk walking for 30‐45 min twice a week (IND)
Number of subjects: 105
Study 29480087 — intervention group
Group type: EXPERIMENTAL
Intervention: Running and brisk walking for 30‐45 min twice a week (GR)
Number of subjects: 105
Study 29480087 — intervention group
Group type: COMPARATOR
Intervention: Control group with no running (C)
Number of subjects: 105
Study 29373392 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE intervention (6 in-person, standardized group sessions focusing on improving lifestyle behaviors)
Number of subjects: 107
Study 29373392 — intervention group
Group type: COMPARATOR
Intervention: Control condition (general advice on AHA diet and exercise guidelines)
Number of subjects: 107
Study 29373392 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGE intervention
Number of subjects: 107
Study 27687353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis-serratus interfascial plane block (PS group, n=32)
Number of subjects: 64
Study 27687353 — intervention group
Group type: COMPARATOR
Intervention: Thoracic paravertebral block (PV group, n=32)
Number of subjects: 64
Study 25560349 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel dressing
Number of subjects: 90
Study 25560349 — intervention group
Group type: COMPARATOR
Intervention: Simple dressing (Control)
Number of subjects: 90
Study 23103771 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based therapy (IT)
Number of subjects: 136
Study 23103771 — intervention group
Group type: COMPARATOR
Intervention: Internet-based self-help (IS)
Number of subjects: 136
Study 20484770 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory task
Number of subjects: 0
Study 20484770 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial attention task
Number of subjects: 0
Study 18360314 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent infection at baseline
Number of subjects: 1462
Study 18360314 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident infection at follow-up
Number of subjects: 1462
Study 16166192 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 500-3000 mg/day
Number of subjects: 16
Study 16166192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 16
Study 12721815 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 43
Study 12721815 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 43
Study 12721815 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 43
Study 10357414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative examination of axillary sentinel lymph nodes by frozen section examination
Number of subjects: 155
Study 10357414 — intervention group
Group type: COMPARATOR
Intervention: Immunocytochemistry
Number of subjects: 155
Study 8949692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms/kg
Number of subjects: 10
Study 8949692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 micrograms/kg)
Number of subjects: 10
Study 8949692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg
Number of subjects: 10
Study 31959139 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (standard-of-care case management plus mHealth intervention)
Number of subjects: 600
Study 31959139 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care case management (control group)
Number of subjects: 600
Study 31959139 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 600
Study 29676864 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Number of subjects: 80
Study 29676864 — intervention group
Group type: COMPARATOR
Intervention: Prefilled Safety Syringe (SS)
Number of subjects: 80
Study 27940700 — intervention group
Group type: EXPERIMENTAL
Intervention: FAmily‐CEntered Advance Care Planning (FACE) pACP intervention (1 session per week for 3 sessions)
Number of subjects: 97
Study 27940700 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (1, Developmental History; 2, Safety Tips; 3, Nutrition/Exercise)
Number of subjects: 97
Study 24862172 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 24
Study 22721657 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V stenting
Number of subjects: 8061
Study 20553667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic relapse prevention (DRP)
Number of subjects: 90
Study 20553667 — intervention group
Group type: COMPARATOR
Intervention: Individual relapse prevention (IRP)
Number of subjects: 90
Study 20553667 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 90
Study 17644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme with group psychotherapy
Number of subjects: 2425
Study 17644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine discontinuation programme without psychotherapy
Number of subjects: 2425
Study 17644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 2425
Study 17644828 — intervention group
Group type: COMPARATOR
Intervention: Control group (1821 long-term users not participating in the programme)
Number of subjects: 2425
Study 17644828 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete discontinuation of benzodiazepines
Number of subjects: 2425
Study 15859929 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (monoclonal antibody against interleukin-2 receptor) for 10 days in kidney transplant recipients
Number of subjects: 120
Study 15859929 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (cyclosporin and prednisone) in kidney transplant recipients
Number of subjects: 120
Study 15859929 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (monoclonal antibody against interleukin-2 receptor) for 7 days in heart transplant recipients
Number of subjects: 120
Study 15859929 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (cyclosporin, prednisone, and OKT3) in heart transplant recipients
Number of subjects: 120
Study 12190808 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB) with 15 ml of ropivacaine (5 mg/ml)
Number of subjects: 45
Study 12190808 — intervention group
Group type: COMPARATOR
Intervention: Subacromial bursa block (SUB) with 15 ml of ropivacaine (5 mg/ml)
Number of subjects: 45
Study 12190808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) with 15 ml of 0.9% saline
Number of subjects: 45
Study 12190808 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block (ISB)
Number of subjects: 45
Study 12190808 — intervention group
Group type: COMPARATOR
Intervention: Subacromial bursa block (SUB)
Number of subjects: 45
Study 10694933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 20
Study 10694933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10694933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine and ethanol
Number of subjects: 20
Study 10694933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 20
Study 7666018 — intervention group
Group type: EXPERIMENTAL
Intervention: Written guidelines on the prevention of pressure sores
Number of subjects: 33
Study 2534373 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of ipratropium bromide (IPB) followed by 5 mg of salbutamol sulfate (SAS)
Number of subjects: 34
Study 2534373 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of salbutamol sulfate (SAS)
Number of subjects: 34
Study 2534373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential inhaled SAS after IPB
Number of subjects: 34
Study 2534373 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dose of SAS
Number of subjects: 34
Study 2534373 — intervention group
Group type: COMPARATOR
Intervention: Double-dose SAS
Number of subjects: 34
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration and back vibration (A1C1)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration and back roller (A1C2)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous footrest vibration, back vibration and back roller (A1C3)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Footrest vibration alone (A1C4)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Back vibration alone (A2C1)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Back roller alone (A2C2)
Number of subjects: 48
Study 990354 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous back vibration and back roller (A2C3)
Number of subjects: 48
Study 990354 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration/stimulation) (A2C4)
Number of subjects: 48
Study 31882381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative optimization of depth of anesthesia targeting BIS values at 50 ± 10
Number of subjects: 82
Study 31882381 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard depth of anesthesia management)
Number of subjects: 82
Study 31564451 — intervention group
Group type: EXPERIMENTAL
Intervention: HBR + sticker group
Number of subjects: 3616
Study 31564451 — intervention group
Group type: EXPERIMENTAL
Intervention: HBR-only group
Number of subjects: 3616
Study 31564451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3616
Study 26592195 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy
Number of subjects: 124
Study 26592195 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 124
Study 26276354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen + Octreotide LAR (TAM + OCT)
Number of subjects: 1560
Study 26276354 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 1560
Study 23142202 — intervention group
Group type: EXPERIMENTAL
Intervention: PRX302
Number of subjects: 92
Study 23142202 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 92
Study 21720704 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + low-dose IL-2 (CT+IL-2)
Number of subjects: 241
Study 21720704 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 241
Study 19695392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg oral dose on day 1)
Number of subjects: 12
Study 19695392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (on day 1)
Number of subjects: 12
Study 16427212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation (RT)
Number of subjects: 277
Study 14524509 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET) combined with supervised neuromuscular re‐education and resistance training
Number of subjects: 19
Study 14524509 — intervention group
Group type: COMPARATOR
Intervention: Supervised neuromuscular re‐education and resistance training
Number of subjects: 19
Study 11109647 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28
Study 11109647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9019177 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution group (6% hydroxyethyl starch 200/0.5, aimed haematocrit of 30%)
Number of subjects: 50
Study 9019177 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution group
Number of subjects: 50
Study 9019177 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 1550909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual tablets
Number of subjects: 8
Study 1550909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release tablets
Number of subjects: 8
Study 1550909 — intervention group
Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 8
Study 1550909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablets
Number of subjects: 8
Study 2408897 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP
Number of subjects: 53
Study 2408897 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 53
Study 29745307 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance program, twice a week for 10 weeks
Number of subjects: 20
Study 27865961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime major depressive disorder (L-MDD)
Number of subjects: 1285
Study 27865961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime generalized anxiety disorder (L-GAD)
Number of subjects: 1285
Study 24923623 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention (STRIDE website access)
Number of subjects: 0
Study 24923623 — intervention group
Group type: COMPARATOR
Intervention: Control group (pedometer only)
Number of subjects: 0
Study 22377840 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ultrasound followed by surgical repair based on ultrasonographic findings
Number of subjects: 92
Study 22377840 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnosis based on history of trauma and physical examination
Number of subjects: 92
Study 20381248 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone-induced hypocortisolism
Number of subjects: 20
Study 20381248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18694477 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct electronic referral and booking for outpatient surgery (one stop)
Number of subjects: 120
Study 18694477 — intervention group
Group type: COMPARATOR
Intervention: Traditional patient pathway (outpatient clinic visit prior to surgery)
Number of subjects: 120
Study 15866630 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab (1 mg/kg in two doses; preoperatively and on day 14) combined with steroids, mycophenolate mofetil (initial dose of 2 g/d), and tacrolimus (0.1 mg/kg per day).
Number of subjects: 119
Study 12063522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with Dermatophagoides pteronyssinus extract encapsulated in liposomes
Number of subjects: 55
Study 12063522 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (empty liposomes)
Number of subjects: 55
Study 9457941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (Crinone 8%) administered twice daily from day 14, containing 90 mg of micronized progesterone.
Number of subjects: 72
Study 9457941 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) progesterone, 100 mg administered from cycle days 15 to 27.
Number of subjects: 72
Study 7620297 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 10
Study 7620297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2234874 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (26 patients)
Number of subjects: 103
Study 2234874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (26 patients)
Number of subjects: 103